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A B S T R A C T
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential 
for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by 
analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies 
for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh 
nebulizers as a promising approach for the treatment of COVID-19.   
1. mAbs as a platform for the rapid deployment of highly
targeted antivirals
The advantages of mAb therapies are manifold. Currently, most mAb 
therapeutics against viruses are isolated from B-cells of patients who 
survived a prior infection, a strategy motivated by the assumption that 
some of the isolated mAbs may confer a survival benefit. High 
throughput screening, coupled with microfluidics and single cell 
sequencing, allows many B-cells to be screened quickly, enabling rapid 
isolation of mAbs with exceptionally high potency within weeks [1–3], a 
task that previously required many months of iterative screening and 
optimization. Unlike small molecule antivirals, the specificity of mAbs 
for viral antigens contributes to both their efficacy and safety, and likely 
lowers the regulatory requirements prior to initiating human studies. 
Concerns of viral escape can be minimized by combining complemen-
tary pairs of mAbs [4,5]. The processes of developing, manufacturing, 
and advancing mAb therapies into the clinic are well understood. These 
biotechnological advances underpin how companies such as Eli Lilly and 
Regeneron have been able to advance unique mAb therapies into the 
clinic within months, and underscore the promise of mAb therapies as an 
interim therapeutic approach for COVID-19 until effective vaccines can 
be developed and broadly implemented among the general population. 
2. Many promising therapeutic mAbs have failed to treat or
prevent ARIs
There are many ARIs for which no vaccine or effective therapies are 
available, including Respiratory Syncytial Virus (RSV), Meta-
pneumovirus (MPV), Parainfluenza Virus (PIV), adenovirus, seasonal 
coronavirus (e.g. NL63-CoV), Rhinoviruses (RV), and others. Notably, 
these ARIs affect millions each year, providing ample financial in-
centives to develop therapeutic interventions. Indeed, the potential 
advantages of mAbs as antivirals have attracted many groups to attempt 
to develop mAbs against these common ARIs over the past two decades. 
Nearly all such efforts have been met with disappointing results. 
Table 1 provides a list of human or humanized mAbs developed as an-
tivirals that have advanced past Phase 1 studies (this list does not 
include mAbs currently under clinical studies, as their eventual outcome 
is not known). None of these mAbs were noted to have major safety 
concerns. Unfortunately, none have shown appreciable efficacy as a 
therapeutic, either, and only one has received approval for prophylaxis 
(palivizumab, also known as Synagis®, which offers only modest effi-
cacy and is recommended only for severely premature infants due to 
limited cost-effectiveness). 
The reasons why so many promising antiviral mAb therapies have 
failed to show clinical efficacy are multifold. For some, clinical devel-
opment was halted due to actual (e.g. suptavumab for RSV 
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[24] and ~ 90 ng/mL for mAb114 [25].
Recent data from advanced trials of anti-SARS-CoV-2 mAbs from Eli
Lilly (LY-CoV555) and Regeneron (REGN-COV2) suggest there is a po-
tential clinical benefit when mAbs are administered early in the course 
of disease, but limited efficacy once patients are hospitalized. Indeed, 
the emergency use authorizations of REGN-COV2 and LY-CoV555 both 
exclude usage in hospitalized patients due to poor results from clinical 
trials, adding to the list of failures of virus-directed mAbs in treating 
hospitalized infections shown in Table 1. Fortunately, the benefits of 
administering mAb therapies earlier in the course of infection, in the 
outpatient setting, were more apparent. With LY-CoV555, treatment was 
associated with a slight decrease in symptom severity up until day 6 (but 
not after), as well as a trend toward decreased hospitalization rates. 
Most surprisingly, however, was that only the 2800 mg group in the LY- 
CoV555 study resulted in a statistically significant reduction in viral 
load by day 11 relative to placebo, whereas the higher dose (7000 mg) 
did not [26]. With REGN-COV2, an interim analysis of results from an 
ongoing phase 2/3 trial showed a reduction in COVID-19-related med-
ical visits by 57% through day 29 in treated patients, relative to placebo. 
However, there was no apparent dose-dependent effect; there was no 
significant difference in virologic or clinical outcomes between the 
2400 mg and 8000 mg dose groups for REGN-COV2 [27]. 
3. An underappreciated pathophysiology of many ARIs
The lung has two distinctive epithelia: a ciliated epithelium that lines
the airways and a specialized epithelium that line the alveolus. The 
differentiated morphology and function of the respiratory tract epithe-
lium exists at the air-liquid interface; epithelial cells grown in sub-
merged culture conditions do not accurately recapitulate the properties 
and functions of authentic respiratory epithelium in vivo. To recapitu-
late the actual pulmonary physiology as closely as possible, culture 
models of human ciliated airway epithelium and alveolar epithelium 
have been developed. The most rigorous model involves culturing 
human nasal or tracheobronchial epithelial cells, which have been 
collected from airway brushings or from cadaver airway tissue, at an air- 
liquid interface to generate a polarized, well-differentiated, ciliated 
airway epithelium [28–30]. This method, commonly referred to as well- 
differentiated human airway epithelial (WD-HAE) culture, has been 
used by numerous investigators over the past two decades to investigate 
how respiratory viruses infect and propagate within the lungs. 
Studies based on WD-HAE cultures have revealed that many viruses 
responsible for common ARIs, including RSV, rhinovirus, influenza, and 
PIV, almost exclusively infect via the apical (airway) side of the respi-
ratory tract, with little to no productive infection when viruses are 
introduced into the basal (serosal) compartment (Fig. 1). More impor-
tantly, these viruses appear to predominantly, if not exclusively, shed 
back into the apical compartment (i.e. into airway mucus secretions), 
with limited to no shedding of virus into the basal compartment. The 
shedding of progeny virus into the apical compartment was first 
described for influenza virus [31–33], and later confirmed for RSV 
[34–38], parainfluenza virus [39], as well as the betacoronaviruses 
Table 1 
Prior attempts to advance mAbs for ARIs have faced barriers in clinical studies.  
Antibody Company Virus Mode Last Stage Status Route Dose IC50 Ref 
CR8020 Crucell Influenza Tx Phase 2 (NCT01992276) Discontinued IV 30 mg/kg ~9–500 ng/ 
mL 
[7] 
CT-P27 Celltrion Influenza Tx Phase 2 (NCT03511066) No new studies 
announced 







Crucell Influenza Tx Phase 2 (NCT02371668) 
and (NCT01992276) 
Discontinued IV 30 mg/kg ~18–2200 ng/ 
mL 
[88,89] 
MEDI8852 MedImmune Influenza Tx Phase 2a (NCT02603952) Halted following Phase 
2a 





MHAA4549A Genentech Influenza Tx Phase 2 (NCT01980966) Halted following two 
Phase 2 studies 





Motavizumab MedImmune RSV Px, 
Tx 
Px: Phase 3 (NCT00129766) 
and (NCT00538785) 
Tx: Phase 2 (NCT00421304) 
BLA withdrawn; not 
effective as Tx [14] 
IM 15 mg/kg 
monthly 
~20 ng/mL [17,93] 
Suptavumab 
(REGN2222) 
Regeneron RSV Px Phase 3 (NCT02325791) Discontinued IM 30 mg/kg ~2–4 ng/mL [94] 
Synagis 
(palivizumab) 
MedImmune RSV Px, 
Tx 
Px: Marketed 
Tx: Not Marketed 
Not Effective (~50% as 
prophylaxis) 
IM 15 mg/kg ~163–360 ng/ 
mL 
[93,95,96] 
TCN-032 Theraclone Influenza Tx Phase 2 (NCT01719874) Discontinued IV 40 mg/kg  [97,98] 
VIS-410 Visterra Influenza Tx Phase 2 (NCT03040141) No clinical activity 
since 2017 





Px = Prophylaxis; Tx = Treatment. 
NCT02325791 [6]) or anticipated (e.g. CR8020 for Influenza [7]) viral 
escape, contributing to a failure to meet primary endpoints [8,9]. 
Motavizumab’s biological license application as an immunoprophylaxis 
against RSV infection was withdrawn due to slightly increased rates of 
injection site reactions that the FDA concluded did not outweigh the 
limited improvements in prophylactic efficacy over palivizumab 
[10,11]. Neither palivizumab [12,13] nor motavizumab [14] showed 
appreciable clinical benefit as therapies for RSV [15]. 
It should be noted that many of the mAbs in Table 1 possess lower 
affinity and neutralizing potency compared to the latest mAbs being 
developed against SARS-CoV-2. Nevertheless, mAbs are generally 
administered at very high doses, such that the mAb levels in the systemic 
circulation should be many orders of magnitude greater than the mAb’s 
actual neutralization potencies (i.e. IC50 or IC80) in vitro. This suggests 
their failure is unlikely to be caused by inadequate dosing of a poorly 
neutralizing mAb. It is also not clear if binding affinity and neutraliza-
tion potencies in vitro predict clinical effectiveness. For instance, there 
did not appear to be an appreciable difference in the prophylactic 
effectiveness of MEDI-8897 vs. motavizumab in early clinical studies 
[16,17] despite ~5–10-fold greater affinity [18] and 9-fold better ac-
tivity in a cotton rat model of RSV infection [19]. Greater neutralization 
potency in vitro also may not predict effectiveness in vivo, as exempli-
fied by an exceptionally potent mAb against Ebola (in vitro) that pro-
vided no efficacy in vivo despite no evidence of neutralization escape 
[20]. 
It is clear that mAb therapies do offer substantial promise for treating 
systemic infections. Recent examples of successful use of systemic 
antiviral mAbs against Ebola Virus include Regeneron’s 3-antibody 
cocktail REGN-EB3, [21] and NIH’s mAb114 [22]. These mAbs 
reduced death rates from the overall mortality of 67% for the Ituri EBOV 
outbreak to ~33.5% and 35.1% of treated patients, respectively [23] 
and to 4.5 and 9.9% in patients with low viral load. It should be noted 
that both treatments required very high doses of mAb (150 mg/kg), 
despite their strong potency in vitro (IC50 of ~60 ng/mL for REGN-EB3 
HKU1 [40], SARS-CoV-1, and now SARS-CoV-2 [41]. Thus, apical 
shedding of virus and subsequent reinfection appears to be the primary 
mode responsible for the spread of these viruses from the upper res-
piratory tract (URT) to the lower respiratory tract (LRT) before 
eventually infecting the deep lung (alveolar epithelium). This mecha-
nism of apical shedding and propagation is consistent with analysis of 
blood from infected patients that typically showed low to no systemic 
viremia, including those infected by influenza virus [42], RSV [43] and 
MPV [44], and explains why nasal or upper airway rather than blood- 
sampling represents the most accurate means of diagnosing ARIs dur-
ing the early stages of infection. It is likely that substantial titers of in-
fectious viruses will only begin accessing the systemic circulation when 
the infection has reached the deep lung and infection and inflammation 
have led to sufficient tissue damage and injury to compromise epithelial 
barrier function [45,46]. 
Similar to ARIs caused by commonly circulating viruses, both SARS- 
Fig. 1. Infection and spread of SARS-CoV GFP in WD- 
HAE cultures over time after apical or basolateral 
inoculation. HAE were inoculated via the apical (left: 
A, C, E, G) or basolateral (right: B, D, F, and H) 
compartments with SARS-CoV GFP and GFP-positive 
cells and assessed over time. Apical inoculation 
resulted in significant numbers of GFP-positive cells 
at 40 h post-infection (C), with extensive spread of 
infection by 90 h post-infection (G). In contrast, 
basolateral inoculation resulted in a low proportion 
of cells positive for GFP only at 68 h post-infection 
(F). These images are representative of duplicate 
cultures from at least three different patient sets. 
Original magnification, 10×. Image reproduced from 
[41].   
The preferential shedding of viruses into the airway mucus as 
infection spreads from the URT to the LRT implies that adequate ther-
apeutic concentrations of mAbs must be achieved in the airway mucus 
secretions to effectively inactivate viruses and limit the continued 
spread of the infection. Greater levels of anti-flu mAb in the nasal mu-
cosa appears to correlate with more rapid elimination of the virus in 
humans [57]. Among the handful of studies that compared inhaled de-
livery of mAbs vs. systemic delivery, inhaled delivery consistently 
afforded greater efficacy. For instance, intransal dosing of anti-influenza 
mAb provided ~3-fold improved survival over IV administration of the 
same mAb [58]. In cotton rats, 160-fold more mAb is required when 
dosed systemically (4 g/kg) in order to match the efficacy of the same 
mAb dosed intranasally (0.025 g/kg) [59]. These preclinical studies 
would suggest that inhaled delivery of anti-SARS-CoV-2 mAbs currently 
under clinical testing will likely achieve comparable efficacy even when 
dosed at a substantially lower dose compared to IV delivery. Given the 
limited mAb supply relative to number of surging cases (e.g. Regeneron 
recently estimated the maximum production capacity for REGN-COV2 
to be ~250,000 doses per month through early 2021, based on cur-
rent IV dosing, whereas 200,000 new cases are being diagnosed every 
day in the United States as of late November 2020), the lower dosage 
requirement for direct inhaled delivery of mAb should be further 
investigated. 
For prophylaxis against RSV infection, we believe the modest clinical 
efficacy observed with palivizumab, motavizumab, and MEDI-8897 is 
likely attributed in part to the low titers of incoming virions during a 
transmission event. However, once an infection is already established in 
the respiratory tract leading to high local viral load, much higher levels 
of mAb dosed systemically is required compared to prophylaxis. Another 
potential shortcoming of systemically delivered therapeutics is the 
relatively slow diffusion of mAbs into the respiratory tract, leading to 
substantial delays before reaching Cmax in the lung. For example, it takes 
3 days of twice-daily dosing for osteltamivir to achieve steady-state drug 
concentrations in the lung [60]. The distribution of mAbs into the lung 
after systemic administration may similarly take a few days before 
reaching Cmax; depending on how quickly mAbs can reach inhibitory 
levels in the airways following systemic dosing, this could mean that 
SARS-CoV-2 is afforded an additional period for exponential increase in 
viral titers and further inflammation. We suspect the frequent failures of 
mAbs as treatment of ARIs is at least partly due to the limited and/or 
delayed distribution of antiviral mAbs into the airway mucus secretions. 
In contrast to systemic delivery, administering antiviral mAbs 
directly into the airways offers several important advantages. First, 
Fig. 2. Preferential apical infection and shedding of 
progeny viruses in the respiratory tract. SARS-CoV-2 
deposited in the upper respiratory tract can diffuse 
through airway mucus and internalize into airway 
epithelial cells by binding to ACE2. The red X’s 
indicate that SARS-CoV-2 does not typically spread 
from an infected cell laterally to a neighboring cell or 
through shedding into the basal compartment. 
Instead, SARS-CoV-2 is preferentially shed from 
infected cells from the apical side, back into the 
airway fluids, in which it diffuses to the apical face of 
neighboring cells, interacting with ACE2 and initi-
ating the process of cellular entry. (For interpretation 
of the references to colour in this figure legend, the 
reader is referred to the web version of this article.)   
CoV-1 and SARS-CoV-2 appear to spread infection through the respira-
tory fluids at the apical airway surface (Fig. 2). Apical infection and 
shedding is consistent with the apical localization of their common re-
ceptor, ACE2, to the apical membrane of human airway epithelium in 
vivo and in WD-HAE cultures [41,47]. It also agrees with clinical reports 
to date that suggest relatively limited viremia of SARS-CoV-2 (i.e. in-
fectious viruses in the blood) before the disease has progressed to more 
severe infection, hyper-inflammation, and lung injury in the more 
fragile alveolus [48]. This gradient of progression of virus infection and 
extent of disease also agrees with the lag between the first symptoms of 
virus infection in the URT to when these patients begin to experience 
dyspnea (5–7 days after symptoms [49,50]). 
4. Systemic vs. inhaled delivery of antiviral mAb therapies using 
vibrating mesh nebulizers
The therapeutic mAbs listed in Table 1 were all administered sys-
temically to patients by either intramuscular (IM) or intravenous (IV) 
injection. Whether these administration routes are optimally suited for 
neutralizing viruses in the apical side of the respiratory tract is highly 
questionable. We believe the administration route, together with the 
timing of initiating treatment relative to the stage of the infection, are 
two factors that substantially impact the efficacy of mAb therapies. 
The pharmacokinetics of systemically administered mAbs have been 
reviewed in great detail in excellent prior publications [51,52]. Notably, 
antibodies are large (~150 kDa for IgGs), hydrophilic molecules with a 
correspondingly low volume of distribution and slow kinetics of distri-
bution out of the plasma, leading to limited passive transport of IgG from 
the circulation to mucosal surfaces. Although IgM and secretory IgA can 
be directly secreted into the airway fluids through a mechanism relying 
upon transcytosis across epithelial cells [53,54], IgG does not benefit 
from the same active mechanism in the lung. This makes the distribution 
of IgG antibodies into the lung in sufficient quantities for efficacy 
exceedingly challenging and necessitates a very systemic high dose, 
relying on a small fraction of the dose to make it to the site of infection. 
Detailed pharmacokinetic studies in primates suggest the concentration 
of systemically administered mAb is roughly ~500–2000 fold lower in 
broncheoalveolar lavage fluid (BALF) compared to plasma [55,56]; our 
recent, unpublished studies in neonatal lambs also yielded a comparable 
magnitude difference in BALF vs. plasma mAb concentration following 
IM delivery. 
5. The best time to treat SARS-CoV-2?
COVID-19 is predominantly a respiratory disease, with early infec-
tion in the upper airways and progression to lower airway disease over 
time. In severe cases of COVID-19, infections in the deep lung result in 
severe inflammation, leading to Acute Respiratory Disease Syndrome 
(ARDS). The hyperinflammatory response and associated cytokine storm 
represents the primary driver of mortality [74]. Indeed, respiratory 
failure alone accounts for 53% of the mortality, and respiratory failure 
coupled with heart failure accounts for another 33%; thus, 86% of 
COVID-19 deaths are directly associated with respiratory failure [27]. At 
later stages of infection, COVID-19 patients also often face a myriad of 
systemic complications including cardiac arrest, brain inflammation 
[75–78], and require ICU care and ventilator support [79]. By then, even 
when the viral load can be quickly controlled, patients still face 
inflammation-associated morbidities and diverse organ damage, as 
shown in some early results from convalescent serum studies [80]. 
Finally, pulmonary fibrosis developed in ~33% of patients who survived 
MERS [81] and SARS [82]; this permanent disability appears to also be 
common among hospitalized patients who survived COVID-19 [83]. We 
believe these realities motivate exploring interventions that can be 
administered soon after an outpatient diagnosis, prior to hospitalization, 
to halt SARS-CoV-2 infection from spreading past the lower respiratory 
tract, inducing hyperinflammation within the lung, and infecting other 
organs. 
Currently, to minimize the burden on the healthcare system, the 
clinical practice in the U.S. is to send most patients who receive a 
positive diagnosis of COVID-19 home, and only hospitalize those who 
experience dyspnea and require supportive care. Unfortunately, by the 
time patients present to the hospital with severe symptoms, the window 
of opportunity to avoid pulmonary inflammation and systemic spread of 
the infection may have already lapsed. Furthermore, the average dura-
tion of hospitalization for COVID-19 patients ranges from 15 to 20 days. 
Even if a mAb therapy for hospitalized patients turns out to be highly 
effective in reducing deaths and shortening the hospitalization stay, 
such therapies will only modestly reduce the burden on the healthcare 
system. 
An alternative approach for mAb-based intervention is to passively 
immunize all high-risk individuals to prevent initial infections and/or 
limit the spread of SARS-CoV-2 infection to the more vulnerable lower 
airways and alveolus. Unfortunately, the manufacturing capacity to 
produce sufficient mAb to passively immunize large populations is 
simply not available. Assuming the same 15 mg/kg dose used to 
passively immunize infants with MEDI-8897 for RSV and the use of a 
highly potent mAb with an IC50 comparable to the most potent mAbs 
currently being advanced for COVID-19, even passively immunizing just 
1000 subjects would require more than 1.2 kg of mAb. Passively 
immunizing six million people (i.e., ~2% of the USA) would likely 
exhaust the entire manufacturing capability of a typical large pharma-
ceutical company. 
Based on the apical pattern of infection and spread of SARS-CoV-2 
and the possibility to directly delivery mAb to the lung airways using 
VMNs, we propose an alternative strategy for early intervention that 
focuses on administering nebulized mAb therapies to high-risk patients 
as soon as they receive a positive RT-PCR-based SARS-CoV-2 diagnosis. 
The median time from first symptoms to hospitalization and ARDS have 
been estimated to be in the range of 5–7 and 8 days, respectively 
[75,84–86]. Given the accelerating deployment of rapid diagnostics, we 
believe it is increasingly likely that patients will be diagnosed when 
infections are still largely restricted to the URT, with limited LRT 
involvement. We believe this represents a golden window of opportunity 
for intervening prior to the development of significant lower airway and 
systemic morbidities. Initiating a mAb therapy immediately following 
outpatient diagnosis may effectively reduce spread of virus infection 
into the distal airways and alveolus, thus reducing the likelihood of 
subsequent pulmonary complications that lead to hospitalization. As 
noted above, nebulization may also substantially reduce the overall dose 
of mAb needed per patient, which would increase the scalability of such 
an approach to a much larger patient population. By potentially pre-
venting hospitalization (rather than simply shortening duration of hos-
pitalization) early nebulized mAb therapy against SARS-CoV-2 may 
greatly reduce the burden on hospital systems should the number of 
COVID-19 patients continue to climb. 
6. Conclusions
Technological advances have allowed pharma and biotech com-
panies to identify lead mAb candidates and advance them into Phase 1 
studies on the order of months, an impressive feat in advancing life- 
saving therapies for the millions of patients infected with SARS-CoV-2. 
Coupling these ultrapotent therapeutic mAb candidates with advances 
in rapid diagnostics potentially enables an early intervention against 
COVID-19 that is distinct from classical passive immunization and sys-
temic therapy. We believe early inhaled mAb therapy represents an 
additional modality for mAb-based therapies that should be assessed in 
parallel with the systemic mAb-based therapies that have shown early 
signs of clinical benefit, offering the potential for more effective treat-
ments that minimize the progression to severe pulmonary disease and 
hospitalization, while minimizing the dose of mAb needed and thus 
enabling treatment of more patients. Beyond addressing the current 
COVID-19 pandemic outbreak, early intervention via direct nebulized 
delivery of mAb may also be a promising strategy to treat ARIs caused by 
commonly circulating pathogens or newly emerging pathogens in future 
inhaled mAbs are immediately available to exert antiviral activity as 
they deposit into airway mucus secretions, the site of virus infection and 
spread. This approach effectively enables earlier intervention during the 
exponential growth phase of viral infection. Relative to systemic 
administration, inhalation either greatly reduces the amount of mAb 
needed to achieve the same inhibitory concentrations in the lung [58], 
and/or achieves much greater local mAb concentrations in airway 
mucus secretions. Given the large quantities of SARS-CoV-2 that are 
shed into airway mucus secretions, pulmonary delivery of mAb appears 
particularly well suited to address the spread of the infection within the 
lung. Given the large quantities of endogenous IgG that are already 
present in airway mucus secretions, inhaled mAb therapies are also 
likely to be well tolerated. Finally, by harnessing Fc-mucin interactions 
[61–64], inhaled mAbs may also facilitate rapid elimination of viruses 
from infected airways through mucus clearance mechanisms including 
muco-ciliary mucus transport and/or cough clearance [65], thereby 
physical eliminating the viral antigens that drive pulmonary hyper-
inflammation. Consistent with the aforementioned advantages of direct 
delivery into the lung as well as the apical route of infection and spread 
of these viruses, prior work has shown that human mAbs delivered 
directly into the lung are highly efficacious [58,59,66,67], and more 
effective than the same mAbs introduced systemically [58,59]. 
Inhaled delivery of mAbs requires a delivery device that is effective 
and efficient. Vibrating mesh nebulizers (VMNs) represent an attractive 
approach for the pulmonary delivery of proteins and antibodies as VMNs 
can: 1) deliver a high dose of mAb to the airways while keeping the total 
volume relatively low [68]; and, 2) achieve uniform dispersion 
throughout the airways [68–71]. Further, by generating aerosols using a 
vibrating mesh, protein degradation is kept to a minimum, unlike jet or 
ultrasonic nebulizers, which rely on heating elements. Whereas tradi-
tional jet nebulizers possess only a ~ 10% delivery efficiency, the latest 
VMNs exceed 60% and directly avoid problems associated with hygro-
scopic growth and agglomeration of proteins - common challenges for 
dry powder formulations of proteins [72,73]. VMNs also directly avoid 
the coordinated breath inhalation frequently required for dry powder or 
metered dose inhalers, which can be difficult for geriatric and pediatric 
patients. VMNs are already routinely used at home and in outpatient 
settings. 
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